Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.

European journal of cancer (Oxford, England : 1990) - 1 May 2018

Gatalica Zoran, Xiu Joanne, Swensen Jeff, Vranic Semir

Abstract excerpt

BACKGROUND: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for several specific cancer types. A comprehensive survey of predictive biomarkers to immune checkpoint blockade in CUP were explored in this study. METHODS: About 389 cases of CUP were analysed for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to PBRM1 gene

Share to Microsatellite Instability

Share to Mutation

Share to Neoplasms, Unknown Primary

Source

Identifiers

PMID: 29571084
DOI: 10.1016/j.ejca.2018.02.021

Genes

APC
JAK2
KRAS
MDM2
PBRM1
SMARCA4
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.PMID 29571084Read ↗

Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.Semantic proximity Read ↗

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.Semantic proximity Read ↗

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.Semantic proximity Read ↗

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.Semantic proximity Read ↗

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknownSemantic proximity Read ↗

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.Semantic proximity Read ↗

Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers.Semantic proximity Read ↗

Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.Semantic proximity Read ↗

Cancer of unknown primary.Semantic proximity Read ↗

Real-world data analysis of patients with cancer of unknown primarySemantic proximity Read ↗

Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.